CSPHF (CStone Pharmaceuticals) Research & Development: $43.94 Mil (TTM As of Dec. 2025)


CSPHF CStone Pharmaceuticals CSPHF
38 GF Score
Price $0.59
GF Value $0.15
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is CStone Pharmaceuticals Research & Development?

CStone Pharmaceuticals CSPHF -14.46% 38 Research & Development is $43.94 Mil as of Dec. 2025. GuruFocus rates CSPHF with a GF Score™ of 38/100 and a GF Value™ of $0.15 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. CStone Pharmaceuticals's Research & Development for the six months ended in Dec. 2025 was $29.30 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $43.94 Mil.

CStone Pharmaceuticals  (OTCPK:CSPHF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

CStone Pharmaceuticals Research & Development Related Terms

CStone Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for CStone Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CStone Pharmaceuticals Research & Development Chart

CStone Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 204.88 88.09 73.92 18.50 44.23

CStone Pharmaceuticals Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.76 9.13 9.40 14.65 29.30
CSPHF
38GF Score
CStone Pharmaceuticals CSPHF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CStone Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $43.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $43.94 Mil mean?
CStone Pharmaceuticals (CSPHF) has a Research & Development of $43.94 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on CStone Pharmaceuticals and its competitors.
Is CStone Pharmaceuticals' Research & Development too high?
CStone Pharmaceuticals' current Research & Development is $43.94 Mil. Overall, CStone Pharmaceuticals has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CStone Pharmaceuticals' Research & Development compare to VRTX and REGN?
CStone Pharmaceuticals' Research & Development of $43.94 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on CStone Pharmaceuticals and its competitors. CStone Pharmaceuticals's current Research & Development is $43.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CStone Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, CStone Pharmaceuticals (CSPHF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $0.59 — trading 296.3% above its estimated fair value. The current Research & Development is $43.94 Mil. CStone Pharmaceuticals' overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For CStone Pharmaceuticals (CSPHF), the current Research & Development is $43.94 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CStone Pharmaceuticals (CSPHF) Overvalued in 2026?

Based on GuruFocus' analysis, CStone Pharmaceuticals stock appears to be overvalued. The current stock price of $0.59 is trading 296.3% above its estimated GF Value™ of $0.15. GuruFocus considers CStone Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for CSPHF:

  • Research & Development: $43.94 Mil
  • GF Value™: $0.15 vs. price of $0.59 (296.3% above fair value)
  • GF Score™: 38/100 with 7 warning signs

No single metric tells the full story. See the CSPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CStone Pharmaceuticals Business Description

Other Exchanges 02616:Hong KongPH4:Germany
Address 218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Suzhou, CHN, 215123
CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The Group has been operating in one reportable segment, being the research and development of high-complex biopharmaceutical products, the sale of pharmaceutical products, and provide license of its IP or commercialisation licenses to customers.
38GF Score

Get the complete analysis for CSPHF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.59
Price
$0.15
GF Value